BethDianeKirkpatrickMD
Infectious Disease • Burlington, VTAssociate Professor, Medicine, University of Vermont College of Medicine
Are you Dr. Kirkpatrick?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 Colchester Ave
Fletcher Allen Health Care
Burlington, VT 05401Phone+1 802-847-4594
Summary
- Dr. Beth Kirkpatrick, MD is an infectious disease specialist in Burlington, Vermont. She is currently licensed to practice medicine in Vermont and Maryland. She is an Associate Professor at University of Vermont College of Medicine.
Education & Training
Albany Medical CollegeClass of 1988
Certifications & Licensure
VT State Medical License 1999 - 2026
MD State Medical License 1996 - 2000
American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Associations Between Histo-blood Group Antigen Status in Mother-Infant Dyads and Infant Oral Rotavirus Vaccine Immunogenicity in Rural Zimbabwe.Joshua Pun, Ceri Evans, Bernard Chasekwa, James A Church, Ethan Gough
The Journal of Infectious Diseases. 2025-02-04 - Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome.Camilla Strother, Nicole Bouffard, Olha Smolynets, Nancy R Graham, Evan A Elko
The Journal of Investigative Dermatology. 2024-12-27 - 1 citationsDifferences in Rotavirus Shedding and Duration by Infant Oral Rotavirus Vaccination Status in Dhaka, Bangladesh, 2011-2014.Jenna Ciszewski, Mami Taniuchi, Benjamin Lee, E Ross Colgate, James A Platts-Mills
The Journal of Infectious Diseases. 2024-07-25
Press Mentions
Colchester's Vernal Biosciences Manufactures the mRNA That’s Revolutionizing MedicineAugust 25th, 2021- Sorely Needed Dengue Vaccine Gets a Boost from Immune ProfilingMay 26th, 2021
- Dengue Immune Function Discovery Could Benefit Much-Needed Vaccine DevelopmentMay 24th, 2021
- Join now to see all
Grant Support
- Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue VaccineUNIVERSITY OF VERMONT & ST AGRIC COLLEGE2019–2029
- Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue VaccineUNIVERSITY OF VERMONT & ST AGRIC COLLEGE2019–2029
- Translational Global Infectious Diseases Research CenterUNIVERSITY OF VERMONT & ST AGRIC COLLEGE2018–2028
- Translational Global Infectious Diseases Research CenterUNIVERSITY OF VERMONT & ST AGRIC COLLEGE2018–2028
- A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic PopulationUNIVERSITY OF VERMONT & ST AGRIC COLLEGE2019–2025
